tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

NGNE Stock Latest News

Neurogene Inc.’s NGN-401: A Promising Gene Therapy for Rett Syndrome
Company AnnouncementsNeurogene Inc.’s NGN-401: A Promising Gene Therapy for Rett Syndrome
2d ago
NGNE
Neurogene’s Strategic Advances and Expanded Embolden Trial Drive Buy Rating
PremiumRatings
Neurogene’s Strategic Advances and Expanded Embolden Trial Drive Buy Rating
20d ago
NGNE
Neurogene’s Favorable Position in CNS Gene Therapy: Buy Rating Backed by Strategic Advantages and Competitive Valuation
PremiumRatings
Neurogene’s Favorable Position in CNS Gene Therapy: Buy Rating Backed by Strategic Advantages and Competitive Valuation
20d ago
NGNE
Neurogene Completes FDA Talks for Rett Syndrome Trial
PremiumCompany Announcements
Neurogene Completes FDA Talks for Rett Syndrome Trial
20d ago
8K
NGNE
Neurogene completes FDA discussion on Embolden trial, announces NGN-401 data
PremiumThe Fly
Neurogene completes FDA discussion on Embolden trial, announces NGN-401 data
20d ago
NGNE
Neurogene’s Strategic Advantage and Undervaluation: A Buy Recommendation with a $45 Target
PremiumRatingsNeurogene’s Strategic Advantage and Undervaluation: A Buy Recommendation with a $45 Target
27d ago
NGNE
Neurogene looks ‘deeply undervalued’ after Taysha news, says H.C. Wainwright
Premium
The Fly
Neurogene looks ‘deeply undervalued’ after Taysha news, says H.C. Wainwright
27d ago
NGNE
TSHA
Short Report: Viking Therapeutics short interest at 5-year high after VK273 data
Premium
The Fly
Short Report: Viking Therapeutics short interest at 5-year high after VK273 data
2M ago
SMR
MLTX
Neurogene’s Clinical Progress and Financial Resilience Underpin Buy Rating Despite Regulatory Challenges
PremiumRatings
Neurogene’s Clinical Progress and Financial Resilience Underpin Buy Rating Despite Regulatory Challenges
3M ago
NGNE
Positive Outlook for Neurogene: Buy Rating Affirmed Amid Clinical Progress and Strong Financial Position
PremiumRatings
Positive Outlook for Neurogene: Buy Rating Affirmed Amid Clinical Progress and Strong Financial Position
3M ago
NGNE
Neurogene’s NGN-401 Gains Favorable Buy Rating Amid Promising Trial Design and Strong Safety Profile
PremiumRatings
Neurogene’s NGN-401 Gains Favorable Buy Rating Amid Promising Trial Design and Strong Safety Profile
3M ago
NGNE
Neurogene Inc. Reports Increased Losses Amid R&D Focus
PremiumCompany Announcements
Neurogene Inc. Reports Increased Losses Amid R&D Focus
3M ago
NGNE
Neurogene Advances NGN-401 Gene Therapy for Rett Syndrome
PremiumCompany AnnouncementsNeurogene Advances NGN-401 Gene Therapy for Rett Syndrome
3M ago
NGNE
NGNE Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
NGNE Upcoming Earnings Report: What to Expect?
3M ago
NGNE
Promising Prospects for Neurogene in Rett Syndrome Treatment: Buy Rating Affirmed
Premium
Ratings
Promising Prospects for Neurogene in Rett Syndrome Treatment: Buy Rating Affirmed
4M ago
NGNE
Optimistic Outlook for Neurogene’s NGN-401 in Rett Syndrome Treatment Boosts Buy Rating
PremiumRatings
Optimistic Outlook for Neurogene’s NGN-401 in Rett Syndrome Treatment Boosts Buy Rating
4M ago
NGNE
Neurogene’s Promising Trial Design and Safety Profile Earns Buy Rating from Analyst Mitchell Kapoor
PremiumRatings
Neurogene’s Promising Trial Design and Safety Profile Earns Buy Rating from Analyst Mitchell Kapoor
4M ago
NGNE
Promising Advancements in Neurogene’s Gene Therapy for Rett Syndrome Drive Buy Rating
PremiumRatings
Promising Advancements in Neurogene’s Gene Therapy for Rett Syndrome Drive Buy Rating
4M ago
NGNE
Neurogene Announces Embolden Trial Design for Rett Syndrome
PremiumCompany Announcements
Neurogene Announces Embolden Trial Design for Rett Syndrome
4M ago
8K
NGNE
Neurogene says on track to share updated clinical efficacy and safety data
PremiumThe FlyNeurogene says on track to share updated clinical efficacy and safety data
4M ago
NGNE
Neurogene announces registrational trial design for Embolden study of NGN-401
Premium
The Fly
Neurogene announces registrational trial design for Embolden study of NGN-401
4M ago
NGNE
Craig-Hallum bullish on Neurogene, initiates with a Buy
Premium
The Fly
Craig-Hallum bullish on Neurogene, initiates with a Buy
4M ago
NGNE
TSHA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >